Mikuteit, Marie and Zschabitz, Stefanie and Stoer, Christine and Herrmann, Edwin and Polifka, Iris and Agaimy, Abbas and Trojan, Lutz and Stroebel, Philipp and Becker, Frank and Wuelfing, Christian and Barth, Peter and Stoeckle, Michael and Staehler, Michael and Stief, Christian and Haferkamp, Axel and Hohenfellner, Markus and Macher-Goeppinger, Stephan and Wullich, Bernd and Noldus, Joachim and Brenner, Walburgis and Roos, Frederik C. and Walter, Bernhard and Otto, Wolfgang and Burger, Maximilian and Schrader, Andres Jan and Hartmann, Arndt and Steffens, Sandra and Erlmeier, Franziska (2022) The prognostic impact of Claudin 6 in papillary renal cell carcinoma. PATHOLOGY RESEARCH AND PRACTICE, 231: 153802. ISSN 0344-0338, 1618-0631
Full text not available from this repository. (Request a copy)Abstract
Background: Claudins are promising biomarkers for diagnosis and prognosis or targets for treatment. They play a major role in signal transduction and are important in nearly all aspects of tumorigenesis. Claudin 6 is a member of the claudin family and is part of the tight junction molecule. It is reactivated in several cancer types and serves as prognostic marker in, for example, gastric, breast or non small cell lung cancer. The prognostic role of Claudin 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), is still unclear. Patients and Methods: The patients' sample collection was a joint collaboration of the PANZAR consortium. Patients' medical history and tumor specimens were collected from n = 240 and n = 128 patients with type 1 and 2 pRCC, respectively. Expression of Claudin 6 was determined by immunohistochemistry. Results: In total, Claudin 6 staining was positive in 55 of 240 type 1 and 30 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed an overall survival of 84% for Claudin 6-compared to 78% for Claudin 6 + in pRCC type 1 tumors (p = 0.449, log-rank) and 68% for Claudin 6-compared to 65.4% for Claudin 6 + in pRCC type 2 tumors (p = 0.364, log-rank). Conclusion: In this study, claudin 6 expression showed no significant association regarding overall survival (OS) and therefore did not qualify as a prognostic marker in pRCC. Future studies will have to determine, whether Claudin 6 plays a prognostic role in other RCC entities. In addition, the function of Claudin 6 as a predictive marker for therapeutic approaches has to be evaluated in future studies.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SURVIVAL; EXPRESSION; UTILITY; Claudin 6; Papillary renal cell carcinoma; Prognosis; Survival |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Dec 2023 07:12 |
| Last Modified: | 13 Dec 2023 07:12 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58785 |
Actions (login required)
 |
View Item |
